Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update

doi:10.1016/j.jfma.2020.06.008

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23374

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23374

Title:	Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update
Authors:	Chan, TC;Wu, NL;Wong, LS;Cho, YT;Yang, CY;Yu, Y;Lai, PJ;Chang, YT;Shih, IH;Lee, CH;Chu, CY
Keywords:	Atopic dermatitis;Consensus;Treatment
Date:	2021
Issue Date:	2022-08-05T09:36:15Z (UTC)
Publisher:	ELSEVIER TAIWAN
ISSN:	0929-6646
Abstract:	Background/Purpose: Atopic dermatitis (AD) is a chronic inflammatory disease commonly seen in children and increasingly recognized in adults. With recent advances in the therapeutic development for AD, the Taiwanese Dermatological Association (TDA) established a committee to update the consensus for AD management in Taiwan. This report describes the 2020 updated consensus for the management of AD. Methods: A panel of 11 core members was convened to review and discuss aspects of AD management and draft recommendation during the first two meetings. The 2015 TDA consensus and the 2017 European guideline, along with recent peer-reviewed articles, serve as the foundation for the update. In the third meeting, AD expert dermatologists selected on a national scale were invited to vote on the final statements. A total of 27 dermatologists attended the final meeting. The consensus was achieved when ratings of 7-9 (out of a total score of 9) accounted for >= 75% of the total votes. Results: Consensus was achieved on the therapeutic options for AD by lines of treatment. A treatment algorithm was presented to illustrate the place of each modality in terms of basic care, acute disease control, and maintenance therapy. Special considerations for the pediatric population, as well as for women during pregnancy and lactation, are discussed. Conclusion: Topical corticosteroids with long-term emollient-based therapies remain the cornerstone of AD treatment. Systemic treatments are indicated when topical therapies and phototherapy fail to control the disease. The recent approval of dupilumab and emerging targeted therapies are expected to bring significant clinical benefit for patients whose disease is inadequately managed by existing options. Copyright (C) 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC.
URI:	http://dx.doi.org/10.1016/j.jfma.2020.06.008 https://www.webofscience.com/wos/woscc/full-record/WOS:000599907800018 https://ir.csmu.edu.tw:8080/handle/310902500/23374
Relation:	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION ,2021,v120,issue 1, P429-442
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	203	View/Open

Loading...